ImmunityBio (IBRX) Slashes 9% on Lack of Leads

Core Viewpoint - ImmunityBio, Inc. (NASDAQ:IBRX) has experienced significant stock price decline, dropping 9.13% to $2.09 amid investor portfolio repositioning ahead of the Piper Sandler 37th Annual Healthcare Conference [1] Financial Performance - The company narrowed its net loss attributable to shareholders by 21.6% to $67.25 million from $85.73 million year-on-year, attributed to increased product revenues and reduced related-party interest expenses [3] - Revenues surged by 425% to $32.06 million from $6.1 million year-on-year, driven by strong sales of its non-muscle-invasive bladder cancer treatment, Anktiva [4] Market Sentiment - Investors are closely monitoring the company's business updates and outlook regarding its clinical pipelines, particularly in light of the upcoming healthcare conference [2]